https://european-biotechnology.com/wp-content/uploads/2024/04/_c__gerald_pixabay.2com.jpg643960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-03-02 16:33:012024-07-12 12:58:27Money for AI-powered drug discovery
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
There is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
https://european-biotechnology.com/wp-content/uploads/2024/04/Kimberley_Shepard_2021_adjusted_extended-2.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-03-01 16:37:352024-04-02 15:34:24Inhalation: the potential for faster onset and fewer side-effects
https://european-biotechnology.com/wp-content/uploads/2024/04/Geldbaum-pixabay.jpg340465Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-03-01 10:08:482024-07-12 12:56:20German HTGF IV fund closes at €493m
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
https://european-biotechnology.com/wp-content/uploads/2024/04/Abivax.jpg500839Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-22 21:48:132024-07-12 12:52:31Abivax SA raises €130m to advance obefazimod to Phase III
https://european-biotechnology.com/wp-content/uploads/2024/04/EB.com_Mark_Chadwick_Ingenza_kl.jpg12501245Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2023-02-22 11:14:322024-07-16 17:18:00Ingenza gets a new strategic business advisor
https://european-biotechnology.com/wp-content/uploads/2024/04/Devonyu.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-02-21 15:27:362024-07-12 12:51:14Paleo raised € 12 m in Series A financing round
Money for AI-powered drug discovery
Latest NewsAntiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
Confo Therapeutics and Lilly partner to advance CFTX-1554
Latest NewsDrug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
Inhalation: the potential for faster onset and fewer side-effects
Sponsored PublicationsThere is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonza’s Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
German HTGF IV fund closes at €493m
Latest NewsThe fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m
Oxford Biomedica changes management
AppointmentsFormer Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
5 Alarm Bio Ltd raises £500K in seed round
Latest NewsBritish anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
High blood pressure reprograms immune system
Latest NewsInterferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
Abivax SA raises €130m to advance obefazimod to Phase III
Latest NewsFrench Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
Ingenza gets a new strategic business advisor
AppointmentsDr Mark Chadwick will bring extensive industry knowledge to his new role as Strategic Business Advisor at UK-based Ingenza Ltd.
Paleo raised € 12 m in Series A financing round
Latest NewsMyoglobin producer Paleo NV has closed a € 12 m Series A round led by DSM Venturing and Planet A Ventures.